Resveratrol-loaded solid lipid nanoparticles versus nanostructured lipid carriers: Evaluation of antioxidant potential for dermal applications

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 1841-1850

  Gokce, Evren H ^a   Korkmaz, Emrah ^a   Dellera, Eleonora ^b   Sandri, Giuseppina ^b   Cristina Bonferoni, M ^b   Ozer, Ozgen ^a  

^a EGE UNIVERSITY   (Turkey)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

Nanostructured lipid carriers; Resveratrol; Solid lipid nanoparticles

Indexed keywords

DRUG CARRIER; GLYCEROL BEHENATE; MIGLYOL; NANOSTRUCTURED LIPID CARRIER; POLOXAMER; POLYSORBATE 80; REACTIVE OXYGEN METABOLITE; RESVERATROL; SOLID LIPID NANOPARTICLE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BIOACCUMULATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOFLUOROMETRY; CYTOTOXICITY TEST; DIFFERENTIAL SCANNING CALORIMETRY; EX VIVO STUDY; FLUORESCENCE ANALYSIS; HUMAN; HUMAN CELL; LIPID ANALYSIS; MELTING POINT; NANOANALYSIS; NONHUMAN; NORMAL HUMAN; PARTICLE SIZE; PROCESS OPTIMIZATION; RAT; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL;

ANALYSIS OF VARIANCE; ANIMALS; ANTIOXIDANTS; CELL SURVIVAL; DERMIS; DRUG CARRIERS; EPIDERMIS; FLOW CYTOMETRY; HUMANS; LIPIDS; NANOPARTICLES; PARTICLE SIZE; RATS; STILBENES;

RATTUS; RICE STRIPE VIRUS;

EID: 84870368353     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S29710     Document Type: Article

References (35)

1. Montesano-Gesualdi N, Chirico G, Catanese MT, Pirozzi G, Esposito F. AROS-29 is involved in adaptive response to oxidative stress. Free Radic Res. 2006;40(5):467-476.
2. Black HS, de Gruijl FR, Forbes PD, et al. Photocarcinogenesis: an overview. J Photochem Photobiol B. 1997;40(1):29-47.
3. Huei R, Neta P. Chemistry of reactive oxygen species. In: Gilbert DL, Colton CA, editors. Reactive oxygen species in biological systems: An interdisciplinary approach. New York: Springer; 2002: 33-73.
4. Portugal M, Barak V, Ginsburg I, Kohen R. Interplay among oxidants, antioxidants, and cytokines in skin disorders: present status and future considerations. Biomed Pharmacother. 2007;61(7):412-422.
5. Scharffetter-Kochanek K, Wlaschek M, Brenneisen P, Schauen M, Blaudschun R, Wenk J. UV-induced reactive oxygen species in photocarcinogenesis and photoaging. Biol Chem. 1997;378(11):1247-1257.
6. Trenam CW, Blake DR, Morris CJ. Skin inflammation: reactive oxygen species and the role of iron. J Invest Dermatol. 1992;99(6):675-682.
7. Afaq F, Adhami VM, Ahmad N. Prevention of short-term ultraviolet B radiation-mediated damages by resveratrol in SKH-1 hairless mice. Toxicol Appl Pharmacol. 2003;186(1):28-37.
8. van Ginkel PR, Sareen D, Subramanian L, et al. Resveratrol inhibits tumor growth of human neuroblastoma and mediates apoptosis by directly targeting mitochondria. Clin Cancer Res. 2007;13(17):5162-5169.
9. Mehnert W, Mäder K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev. 2001;47(2-3): 165-196.
10. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur J Pharm Biopharm. 2000;50(1):161-177.
11. Jenning V, Gohla SH. Encapsulation of retinoids in solid lipid nanoparticles (SLN). J Microencapsul. 2001;18(2):149-158.
12. Wissing SA, Müller RH, Manthei L, Mayer C. Structural characterization of Q10-loaded solid lipid nanoparticles by NMR spectroscopy. Pharm Res. 2004;21(3):400-405.
13. Müller RH, Runge S, Ravelli V, Mehnert W, Thunemann AF, Souto EB. Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN) versus drug nanocrystals. Int J Pharm. 2006;317(1):82-89.
14. Küchler S, Wolf NB, Heilmann S, et al. 3D-wound healing model: influence of morphine and solid lipid nanoparticles. J Biotechnol. 2010;148(1):24-30.
15. Dingler A, Blum RP, Niehus H, Müller RH, Gohla S. Solid lipid nanoparticles (SLN/Lipopearls)-a pharmaceutical and cosmetic carrier for the application of vitamin E in dermal products. J Microencapsul. 1999;16(6):751-767.
16. Puglia C, Filosa R, Peduto A, et al. Evaluation of alternative strategies to optimize ketorolac transdermal delivery. AAPS Pharm Sci Technol. 2006;7(3):64.
17. Souto EB, Wissing SA, Barbosa CM, Müller RH. Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. Int J Pharm. 2004;278(1):71-77.
18. Teeranachaideekul V, Müller RH, Junyaprasert VB. Encapsulation of ascorbyl palmitate in nanostructured lipid carriers (NLC)-effects of formulation parameters on physicochemical stability. Int J Pharm. 2007;340(1-2):198-206.
19. Pardeike J, Hommoss A, Müller RH. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int J Pharm. 2009;366(1-2):170-184.
20. Teskac K, Kristl J. The evidence for solid lipid nanoparticles mediated cell uptake of resveratrol. Int J Pharm. 2010;390(1):61-69.
21. Gokce EH, Sandri G, Bonferoni MC, et al. Cyclosporine A loaded SLNs: evaluation of cellular uptake and corneal cytotoxicity. Int J Pharm. 2008;364(1):76-86.
22. Jang JH, Surh YJ. Protective effects of resveratrol on hydrogen peroxide-induced apoptosis in rat pheochromocytoma (PC12) cells. Mutation Res. 2001;496(1-2):181-190.
23. Afzal M, Matsugo B, Aoyama K, Takeuchi T. Method to overcome photoreaction, a serious drawback to the use of dichlorofluorescin in evaluation of reactive oxygen species. Biochem Biophys Res Commun. 2003;304(4):619-624.
24. Şenyiǧit T, Sonvico F, Barbieri S, Özer Ö, Santi P, Colombo P. Lecithin/chitosan nanoparticles of clobetasol-17-propionate capable of accumulation in pig skin. J Control Rel. 2010;142(3):368-673.
25. Timms RE. Fractional crystallization-the fat modification process for the 21st century. Eur J Lipid Sci Technol. 2005;107:48-57.
26. Illingworth D. Fractionation of fats. In: Marangoni AG, Narine SS, editors. Physical Properties of Lipids. New York: Marcel Dekker, 2002;411-477.
27. Jenning V, Thünemann AF, Gohla SH. Characterisation of a novel solid lipid nanoparticle carrier system based on binary mixtures of liquid and solid lipids. Int J Pharm. 2000;199(2):167-177.
28. Uner M, Yener G. Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives. Int J Nanomedicine. 2007;2(3):289-300
29. Kaur IP, Kapila M, Agrawal R. Role of novel delivery systems in developing topical antioxidants as therapeutics to combat photoageing. Ageing Res Rev. 2007;6(4):271-288.
30. Souto EB, Muller RH. Nanoparticulate drug delivery systems. Informa Healthcare U S A, Inc. 2007;166:213-234.
31. Trombino S, Cassano R, Muzzalupo R, Pingitore A, Cione E, Picci N. Stearyl ferulate-based solid lipid nanoparticles for the encapsulation and stabilization of beta-carotene and alfa-tocopherol. Colloids Surf B Biointerfaces. 2009;72(2):181-187.
32. Ruktanonchai U, Bejrapha P, Sakulkhu U, et al. Physicochemical characteristics, cytotoxicity, and antioxidant activity of three lipid nanoparticulate formulations of alpha-lipoic acid. AAPS Pharm Sci Tech. 2009;10(1):227-234.
33. Cullis PR, Chonn A, Semple SC. Interactions of liposomes and lipid-based carrier systems with blood proteins: relation to clearance behaviour in vivo. Adv Drug Delivery Rev. 1998;32(1-2):3-17.
34. Hayes ME, Drummond DC, Hong K, et al. Increased target specificity of anti-HER2 genospheres by modification of surface charge and degree of PEGylation. Mol Pharm. 2006;3(6):726-36.
35. Wesołowska O, Kuzdzał M, Strancar J, Michalak K. Interaction of the chemopreventive agent resveratrol and its metabolite, piceatannol, with model membranes. Biochim Biophys Acta. 2009;1788(9):1851-1860.